| 2024-11-07 | +13.52 % |
|
| 2024-10-28 | +2.8 % |
|
| 2024-10-15 | +3.95 % |
|
| 2024-10-07 | -2.24 % |
|
| 2024-09-30 | +0.52 % |
|
| 2024-09-17 | +0.08 % |
|
| 2024-09-04 | -0.93 % |
|
| 2024-08-14 | -1.47 % |
|
| 2024-08-08 | +6.51 % |
|
| 2024-08-02 | -0.75 % |
|
| 2024-06-17 | -0.59 % |
|
| 2024-06-14 | -2.12 % |
|
| 2024-06-07 | +0.48 % |
|
| 2024-06-03 | -0.19 % |
|
| 2024-05-31 | +1.15 % |
|
| 2024-05-29 | -0.77 % |
|
| 2024-05-28 | -0.19 % |
|
| 2024-05-23 | -3.22 % |
|
| 2024-05-22 | -0.78 % |
|
| 2024-05-21 | -0.99 % |
- The article discusses Asymchem Laboratories' new lease agreement to operate a former Pfizer U.K. facility for pharmaceutical development and production in Europe, potentially impacting Viatris (VTRS) stock, which saw a -0.99% decrease. The stock may have gone down due to concerns about competition and potential market shifts resulting from Asymchem's entrance into the European pharmaceutical manufacturing sector.
- The article discusses the financial performance of Idorsia in the first quarter of 2024, including both US GAAP and non-GAAP measures, with a focus on the impact of the Viatris Deal which led to a net gain of CHF 125 million offset by expenses, resulting in a decrease of -0.99% in Viatris(VTRS) stock.
- Asymchem Laboratories (Tianjin) Co., Ltd. has signed a lease agreement to operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories in Sandwich, Kent, to establish its first manufacturing footprint in Europe, planning to employ approximately 100 individuals by the end of 2024, which led to the stock of Viatris (VTRS) going down by -0.99% as a separate tracking of another company's operations impacted investor sentiment.
|
